Satish K. Chitneni
Assistant Professor of Radiology
The major focus of my research is on the design, development and evaluation of novel radiotracers based on small molecules for imaging of specific molecular targets by positron emission tomography (PET). The imaging targets are usually enzymes, cell surface receptors or transporters that are strongly implicated in or markers of diseases. Fluorine-18, which has a half-life of about 110 min, is ideally suited for radiolabeling of small molecules, and permits PET imaging studies for up to 4 h after injection in vivo. Other radioisotopes of interest for PET radiotracer development include carbon-11 and iodine-124, the latter one has a longer half-life (4.2 days) and enables imaging at late time points. Another major area of interest is the use of PET imaging in conjunction with suitable radiotracers for evaluation of novel therapeutics in preclinical studies.
Utilizing the wealth of information available from the cancer genome sequencing studies and The Cancer Genome Atlas (TCGA) studies, efforts are underway to develop radiolabeled probes for PET imaging of isocitrate dehydrogenase 1 (IDH1) mutations, which are present in the vast majority of patients with lower-grade gliomas and secondary higher-grade gliomas. Successful development of imaging methods for mutant IDH1 and other important genetic alterations in gliomas can help in molecular and genetic classification of gliomas noninvasively and in developing novel therapeutics.
Appointments and Affiliations
- Assistant Professor of Radiology
- Faculty Network Member of Duke Institute for Brain Sciences
- Member of the Duke Cancer Institute
- Office Location: 311 Research Drive, 161-I Bryan Research Building, Durham, NC 27710
- Office Phone: (919) 684-7809
- Email Address: email@example.com
- Ph.D. Katholieke Universiteit Leuven (Belgium), 2007
- Zhou, Z; Chitneni, SK; Devoogdt, N; Zalutsky, MR; Vaidyanathan, G, Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation., Bioorganic & Medicinal Chemistry, vol 26 no. 8 (2018), pp. 1939-1949 [10.1016/j.bmc.2018.02.040] [abs].
- Gedeon, PC; Schaller, TH; Chitneni, SK; Choi, BD; Kuan, C-T; Suryadevara, CM; Snyder, DJ; Schmittling, RJ; Szafranski, SE; Cui, X; Healy, P; Herndon, JE; McLendon, RE; Keir, ST; Archer, GE; Reap, E; Sanchez-Perez, L; Bigner, DD; Sampson, JH, A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma., Clinical cancer research : an official journal of the American Association for Cancer Research (2018) [10.1158/1078-0432.ccr-17-0126] [abs].
- Chitneni, SK; Reitman, ZJ; Spicehandler, R; Gooden, DM; Yan, H; Zalutsky, MR, Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors., Bioorganic & Medicinal Chemistry Letters, vol 28 no. 4 (2018), pp. 694-699 [10.1016/j.bmcl.2018.01.015] [abs].
- Chitneni, SK; Reitman, ZJ; Gooden, DM; Yan, H; Zalutsky, MR, Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs., European Journal of Medicinal Chemistry, vol 119 (2016), pp. 218-230 [10.1016/j.ejmech.2016.04.066] [abs].
- Chitneni, SK, IDH1 Mutations in Glioma: Considerations for Radiotracer Development., SM radiology journal, vol 2 no. 1 (2016) [abs].